
CHMP Approves New Therapies for Immune Thrombocytopenia and Other Conditions
The EMA's CHMP recommended approval for two new medicines, Brinsupri for bronchiectasis and Wayrilz for immune thrombocytopenia, while advising against Rezurock for graft-versus-host disease. It also approved extensions for eight existing medicines, withdrew an application for hydrocortisone in preterm infants, confirmed the suspension of Oxbryta for sickle cell disease, and introduced a new administration route for Saphnelo. The meeting's agenda and minutes are forthcoming.
